Edgar v. Teva Pharmaceuticals Industries, Ltd.

District Court, D. Kansas·Decided May 27, 2025·No. 2:22-cv-02501·Unknown

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS

DENA BURGE, LEIGH HOCKETT, JORDAN FURLAN, CRISTINE RIDEY, PATRICIA SAWCZUK, and ANNE ARUNDEL COUNTY, individually and on behalf of all others similarly situated, Case No. 22-cv-2501-DDC-TJJ

Plaintiffs,

v.

TEVA PHARMACEUTICAL INDUSTRIES, LTD., TEVA PHARMACEUTICALS USA, INC., TEVA PARENTERAL MEDICINES, INC., TEVA NEUROSCIENCE, INC., TEVA SALES & MARKETING, INC., and CEPHALON, INC.,

Defendants.

MEMORANDUM AND ORDER

This matter is before the Court on Defendants’ Motion to Compel Non-Parties Burns Charest LLP, Keller Rohrback L.L.P., and Sharp Law LLP (“Law Firms”) to Produce Documents (ECF No. 160). Defendants request an order, pursuant to Fed. R. Civ. P. 45(d)(2)(B)(i), compelling three Law Firms representing the named Plaintiffs in this action to comply with Phase I subpoenas for the production of documents. The Law Firms oppose the motion. As explained below, Defendants’ motion is granted in part and denied in part. I. Nature of the Case and Discovery Dispute Background Plaintiffs—representing a proposed class—allege Defendants and their co-conspirators entered an unlawful reverse payment settlement and conspired to safeguard their monopoly on Nuvigil, a wakefulness drug with the generic name Armodafinil. Plaintiffs allege Defendants agreed to stay out of the EpiPen market, allowing Mylan and Pfizer to maintain their EpiPen

monopoly. In exchange, Plaintiffs contend, Mylan and Pfizer agreed to stay out of the Nuvigil market, allowing Defendants to maintain their Nuvigil monopoly.1 Based on these factual allegations, Plaintiffs assert four claims: (1) a Sherman Act claim; (2) claims for Conspiracy and Combination in Restraint of Trade under various state laws; (3) claims for Monopolization and Monopolistic Scheme under various state laws; and (4) a Racketeer Influenced and Corrupt Organizations Act (“RICO”) claim.2 Early in the case, Defendants filed a motion to dismiss Plaintiffs’ claims as barred by the statute of limitations.3 Judge Crabtree denied Defendants’ motion.4 Pertinent here, he found Plaintiffs’ Sherman Act and RICO claims were subject to a four-year statute of limitations, but Plaintiffs had alleged facts “capable of supporting a plausible finding or inference that fraudulent

concealment and equitable tolling apply to toll the statute of limitations.”5 He further noted a factual dispute exists over whether and when Plaintiffs possessed either actual or constructive

1 Most of this factual background summary of the case is taken from District Judge Crabtree’s Nov. 6, 2024 Mem. & Order (ECF No. 131). 2 Corrected Second Am. Class Action Compl. (ECF No. 129) filed on Nov. 5, 2024. 3 ECF No. 47. 4 Mar. 26, 2024 Mem. & Order (ECF No. 74). 5 Id. at 17. knowledge of their claims and over Plaintiffs’ “diligence in discovering their claims.”6 Judge Crabtree also concluded Plaintiffs plausibly alleged Defendants actively concealed their wrongdoing, but stated Defendants “are free to attempt to persuade the jury that a reasonable plaintiff should’ve had notice of their claims from the press releases or Mylan’s disclosure” regarding the patent litigation settlements.7 He also addressed Defendants’ argument the EpiPen

MDL plaintiffs were represented by several of the same lawyers in this case, noting “[a]s an initial matter, the court can’t rely on the knowledge of plaintiffs’ lawyers” in order to impute plaintiffs’ counsel’s knowledge onto plaintiffs themselves if there is “no indication these plaintiffs had a relationship with their attorneys in 2017.”8 Judge Crabtree’s ruling also suggested a bifurcated approach to discovery with initial discovery focused on the pivotal issue of timeliness.9 The undersigned Magistrate Judge subsequently entered the Phase I Scheduling Order, which limited Phase I Timeliness/Limitations discovery to: [T]he timeliness of Plaintiffs’ claims under the applicable statutes of limitations and any related statute-of-limitations issues, facts, and circumstances, including Defendants’ statute of limitations defense or defenses (and the elements thereof) and the issues of tolling, equitable tolling, and fraudulent concealment (and the elements thereof).10 As part of Phase I discovery, Defendants served subpoenas upon three law firms that represent Plaintiffs in this action: Keller Rohrback, L.L.P. (“Keller”), Sharp Law LLP (“Sharp”),

6 Id. at 36, 39. 7 Id. at 31. 8 Id. at 31–32. 9 Id. at 40. 10 Phase I Sch. Order (ECF No. 92). and Burns Charest LLP (“Burns”). The subpoenas contain four requests: Subpoena Requests 1 and 2 seek documents and communications the Law Firms disseminated soliciting potential plaintiffs for participation, respectively, in the EpiPen MDL and this action. Request 3 seeks documents and communications related to the EpiPen MDL made publicly available via the Law Firms’ websites or any other platform from January 1, 2016 through the present. Request 4 seeks documents and

communications related to this action made publicly available via the Law Firms’ websites or any other platform from January 2021 through the present. The Law Firms served their respective responses to the subpoenas, asserting various objections, including relevance, burden, and privilege. Following and in response to the Court’s February 11, 2025 ruling on Defendants’ motion to compel discovery from Plaintiffs,11 the Law Firms served amended responses and objections to the subpoenas.12 As part of their document productions, Keller and Sharp initially produced “webpages located on [their] own website[s] and advertisements and press releases posted on social media platforms such as Facebook” as screenshots, which are static images of the pages.13 Defendants

claimed the screenshots produced were deficient because: (1) they were produced without the “associated metadata” sufficient to identify the dates made public; (2) they failed to display user interactions with social media posts (e.g., “like,” “share,” or “comment”); and (3) they did not include responsive materials accessible via links in the social media posts.14 Defendants contended

11 Mem. & Order (ECF No. 153). The Court’s order, inter alia, overruled Plaintiffs’ relevance objections and corresponding limitations to post-attorney contact. Id. at 7–11. 12 ECF Nos. 166-5 to 166-7. 13 Fierro Decl. (ECF No. 166-12) ¶ 14; Feb. 25, 2025 Email (ECF No. 166-8) at 3–8 (referencing Sharp’s production of screenshots). 14 Feb. 20 and 25, 2025 Emails (ECF No. 166-8) at 3, 6. the lack of metadata could be corrected through a “proper collection of the requested information via a native export or one of many e-discovery tools available.”15 Keller thereafter supplemented its production for the social media posts.16 Defendants subsequently reported that their own investigation revealed additional online publications regarding the EpiPen MDL litigation the Law Firms never produced. Defendants

attached screenshots of the located publications,17 and requested the Law Firms produce them along with “appropriate metadata.”18 In response, Keller and Sharp stated they did not produce past versions of their websites because they do not maintain or have an archive of them.19 After further email attempts to confer about the Law Firms’ objections to the subpoenas, Defendants timely filed their motion to compel.20 II. Legal Standards Federal Rule of Civil Procedure 45 governs subpoenas served upon non-parties. Under Rule 45(d)(2)(B), if the entity commanded to produce documents serves written objections to the subpoena, the serving party may seek compliance by filing a motion to compel production of the documents.

Free access — add to your briefcase to read the full text and ask questions with AI

Edgar v. Teva Pharmaceuticals Industries, Ltd., (D. Kan. 2025).

Edgar v. Teva Pharmaceuticals Industries, Ltd. (Edgar v. Teva Pharmaceuticals Industries, Ltd.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related